To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children

Inclusion Criteria: * healthy Korean children(age: 10 \~ 17) * In the case of step1 (for step 1) 11\~12 years * who got the basic vaccination(5 times vaccination of diphtheria and tetanus until 6 years old.) * Subjects willing to provide written informed consent and able to comply with the requirements for the study or informed consent was obtained from the subject's legal guardian Exclusion Criteria: * Subjects with antitoxin of diphtheria and tetanus ≥1.0IU/mL (ELISA) * only applicable in step 1 * subjects who have not recovered from the acute disease within 2 weeks * who has experienced the temporary platelet decrease or has the medical history of neurologic complication * who has the medical history of allergic disease related to the components of investigational drug * who has experienced the severe adverse events for the diphtheria and tetanus vaccination * who got the vaccination of diphtheria and tetanus within 5 years * who has not recovered from the acute disease within 2 weeks * who got the treatment of blood product within 3 months * who got the immunoglobulin should have the wash-out period * who be infected from the diphtheria and tetanus * Subjects who are scheduled to participate in other clinical trial studies during the study. * Current participation in a clinical study involving any other drugs including vaccine within 4 weeks of enrollment of the study vaccine. * Subjects who have participated in any other clinical trials within 4 weeks of the administration of the study * Subject who have received adrenocortical hormones or immunosuppressive drug within 4weeks of enrollment * Subjects with a history of chronic disease obstacles to the study. * Subjects who have episode of acute febrile (at least 37.5) after injection of vaccine during the study * Subject who have plan of operation during the study. * Individuals with other clinically significant medical or psychological condition who are considered by the investigator to be ineligible for the study.